Cardiac Safety Profile of Imatinib and Nilotinib In Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Results From ENESTnd.

被引：0

作者：

Larson, Richard A. ^{[1
]}

Hochhaus, Andreas ^{[2
]}

Saglio, Giuseppe ^{[3
]}

Rosti, Gianantonio ^{[4
]}

Lopez, Jose L. ^{[5
]}

Stenke, Leif ^{[6
,7
]}

Nakamae, Hirohisa ^{[8
]}

Goldberg, Stuart L. ^{[9
]}

Wang, Ming-Chung ^{[10
]}

Gallagher, Neil J. ^{[11
]}

Hoenekopp, Albert ^{[11
]}

Ortmann, Christine-Elke

Hughes, Timothy P. ^{[12
]}

Kantarjian, Hagop M. ^{[13
]}

机构：

[1] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[2] Univ Klinikum Jena, Klin Innere Med 2, Jena, Germany

[3] Univ Turin, Div Internal Med & Hematol, Orbassano, Italy

[4] Univ Bologna, Dept Hematol Oncol, Bologna, Italy

[5] Banco Municipal Sangre, Dpt Clin Hematol, Caracas, Venezuela

[6] Karolinska Univ Hosp, Div Hematol, Stockholm, Sweden

[7] Karolinska Inst, Stockholm, Sweden

[8] Osaka City Univ, Grad Sch Med, Osaka 558, Japan

[9] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Div Leukemia, Hackensack, NJ USA

[10] Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Internal Med, Kaohsiung, Taiwan

[11] Novartis Pharma AG, Oncol, Basel, Switzerland

[12] Royal Adelaide Hosp, Dept Haematol SA Pathol, Adelaide, SA 5000, Australia

[13] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

BLOOD | 2010年 / 116卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：944 / 945

页数：2

共 50 条

[31] ENESTND 5-YEAR FOLLOW-UP: CONTINUED BENEFIT OF FRONTLINE NILOTINIB (NIL) COMPARED WITH IMATINIB (IM) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
Hughes, T. P.
le Coutre, P. D.
Jootar, S.
Reiffers, J.
Turkina, A. G.
Saglio, G.
Hochhaus, A.
Kantarjian, H. M.
Kemp, C.
Deng, W.
Menssen, H. D.
Larson, R. A.
HAEMATOLOGICA, 2014, 99 : 236 - 237
[32] The incidence of BCR-ABL mutations in patients (pts) with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) treated with nilotinib or imatinib in ENESTnd: 24-month follow-up
Saglio, G.
Kantarjian, H.
Reiffers, J.
Jootar, S.
Kalaycio, M. E.
Shibayama, H.
Fan, X.
Gallagher, N. J.
Shou, Y.
Larson, R. A.
Hughes, T. P.
Hochhaus, A.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[33] ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Response (EMR) and Sokal Risk At Diagnosis On Long-Term Outcomes
Saglio, Giuseppe
Hochhaus, Andreas
Hughes, Timothy P.
Clark, Richard E.
Nakamae, Hirohisa
Kim, Dong-Wook
Jootar, Saengsuree
Etienne, Gabriel
Flinn, Ian
Lipton, Jeffrey H.
Pasquini, Ricardo
Moiraghi, Beatriz
Kemp, Charisse
Fan, Xiaolin
Menssen, Hans D.
Kantarjian, Hagop M.
Larson, Richard A.
BLOOD, 2013, 122 (21)
[34] Efficacy of Frontline Nilotinib Therapy in Patients. (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP)
Quintas-Cardama, Alfonso
Kantarjian, Hagop M.
Luthra, Rajyalakshmi
O'Brien, Susan
Jabbour, Elias
Borthakur, Gautam
Ravandi, Farhad
Garcia-Manero, Guillermo
Faderl, Stefan
Konopleva, Marina
Wierda, William G.
Burton, Elizabeth
Cortes, Jorge E.
BLOOD, 2011, 118 (21) : 210 - 210
[35] Molecular Responses to Dasatinib and Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Quintas-Cardama, Alfonso
Kantarjian, Hagop
Michor, Franziska
Olshen, Adam
Gonen, Mithat
Jones, Dan
Rios, Mary Beth
O'Brien, Susan
Cortes, Jorge
BLOOD, 2008, 112 (11) : 1114 - 1115
[36] Dasatinib (Versus Imatinib) In Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of Safety and Efficacy by Use of Baseline Medications In the DASISION Trial.
Guilhot, Francois
Kantarjian, Hagop
Shah, Neil P.
Hochhaus, Andreas
Bradley-Garelik, M. Brigid
Dejardin, David
Cortes, Jorge E.
BLOOD, 2010, 116 (21) : 946 - 947
[37] The Incidence of BCR-ABL Mutations and Their Impact on Outcome in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib or Imatinib in ENESTnd: 36-Month Follow-up
Hughes, Timothy P.
Kim, Dong-Wook
Etienne, Gabriel
De Souza, Carmino
Kurokawa, Mineo
Kalaycio, Matt
Saglio, Giuseppe
Larson, Richard A.
Kantarjian, Hagop M.
Hoenekopp, Albert
Shou, Yaping
Yu, Richard
Blakesley, Rick E.
Rosti, Gianantonio
Hochhaus, Andreas
BLOOD, 2011, 118 (21) : 1184 - 1185
[38] PROJECTING THE LONG-TERM SURVIVAL OF NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE (CP) RECEIVING NILOTINIB OR IMATINIB
Botteman, F.
Stephens, J.
Coombs, J.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 348 - 348
[39] Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): Landmark analysis of 4-year (y) data from ENESTnd
Saglio, Giuseppe
Hughes, Timothy P.
Larson, Richard A.
Issaragrilsil, Surapol
Turkina, Anna G.
Steegmann, Juan Luis
Lopez, Jose L.
Nakaseko, Chiaki
Kalaycio, Matt E.
Huguet, Francoise
Kemp, Charisse N.
Fan, Xiaolin
Menssen, Hans D.
Kantarjian, Hagop M.
Hochhaus, Andreas
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[40] Nilotinib Shows Safety and Efficacy in Older Patients (≥ 65 years) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Comparable with That in Younger Patients with Chronic Myeloid Leukemia in Chronic Phase: Results From ENESTnd
Larson, Richard A.
Bunworasate, Udomsak
Turkina, Anna G.
Goldberg, Stuart L.
Dorlhiac-Llacer, Pedro
Lopez, Jose L.
Kantarjian, Hagop M.
Saglio, Giuseppe
Hochhaus, Andreas
Hoenekopp, Albert
Blakesley, Rick E.
Yu, Richard
Gallagher, Neil J.
Clark, Richard E.
Hughes, Timothy P.
BLOOD, 2011, 118 (21) : 1608 - 1609

← 1 2 3 4 5 →